January 2025 in “Indian Journal of Paediatric Dermatology” Biopsy is crucial to correctly diagnose granuloma annulare, which can mimic other conditions like alopecia mucinosa.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
15 citations
,
November 1997 in “Australasian Journal of Dermatology” A combination of oral cyclosporin and PUVA treatment worked well for a severe skin condition called generalized pustular psoriasis.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
20 citations
,
January 2013 in “Evidence-based complementary and alternative medicine” TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
5 citations
,
September 2024 in “Biomolecules and Biomedicine” Total glucosides of paeony may help treat alopecia areata by reducing inflammation and hair loss.
July 2025 in “Journal of Investigative Dermatology” γδ T cells can prevent and treat alopecia areata, offering a new therapy option.
37 citations
,
September 2017 in “Reumatología Clínica” Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
3 citations
,
May 2008 in “Journal of Clinical Oncology” Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
June 2025 in “British Journal of Dermatology” MS treatments can cause significant hair loss, affecting mental health.
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
3 citations
,
September 2021 in “JAAD case reports” Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
1 citations
,
March 1999 in “British journal of rheumatology” Adequate steroid treatment needed to limit bone loss in PMR patients.
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.
Baricitinib works better than methotrexate for severe alopecia areata.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.